Vicarious Surgical, Inc. · OTC:RBOT
Vicarious Surgical — D8 Holdings — SPAC Merger (August 2021)
32 slides from Vicarious Surgical's SPAC merger presentation, Aug 27, 2021
Slide 1: Vicarious Surgical Investor Presentation April 2021
VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 VICARIOUS SURGICAL NVESTOR PRESENTATION APRIL 202,
Slide 2: Disclaimer
Vv DISCLAIMER
Slide 3: Today's Presenters
Vv TODAY'S PRESENTERS ah DONALD TANG ADAM SACHS DAVID STYKA BILL KELLY CELADON PARTNERS € Nir AURIS. #* revance Dreruicen SE CITADEL DEST Deloitte, @ VPrcangus ah MICHAEL PRATT intuitive (=) @2cr200
Slide 4: Transaction Summary
Vv TRANSACTION SUMMARY Vicarious is preparing to go public through a business combination with D8 and is raising STI5 million’ through a PIPE weanous TRANSACTION STRUCTURE Vicarious and D8 announced a definitive business combination agreement on April 15th, 2021 DBis raising $115 million’ through a
Slide 5: Key Investment Highlights
Vv KEY INVESTMENT HIGHLIGHTS GRO. NEXT GENERATION ROBOTICS Ae technoLosy ABILITY TO ADDRESS MOST ABDOMINAL PROCEDURES DESIGNED TO SOLVE MANUAL Sf DEVELOPED IN STEALTH BY AND ROBOT-ASSISTED ) VISIONARY MANAGEMENT TEAM SURGERY SHORTCOMINGS, 22 AND INVESTORS TAPPING INTO A $1368 ONLY ROBOT WITH FO @ MA
Slide 6: Our Team and Investors
“OUR TEAMAND INVESTORS
Slide 7: Visionary Management Team
Vv VISIONARY MANAGEMENT TEAM e a © > ' TP vg JUNE MORRIS ae PRATT apes aerccn Q wii @ MEOEALOFIEER NEERAJ MAINKAR DAVE WILKINSON axRRY GREENE “om ee ADAM SACHS SAMMY KHALIFA DAVID STYKA 6 Nir @ Nir AURIS #* revance eo on i? oumrus inn, Madge
Slide 8: Experienced Board and Advisors, Seasoned Investors
Vv EXPERIENCED BOARD SEASONED AND ADVISORS INVESTORS SELECT EXISTING INVESTORS a. 3) 2 kosla ventures) Re RIC FULOP. Bill Gates EISve eric mAh, Deseo fa |e AE pg 8 HOLDINGS CORP. Du NOTA CURRENT INVESTOR I VICARIOUS
Slide 9: The Problem
Slide 10: The State of Surgery Today
Vv THE STATE OF SURGERY TODAY OPEN SURGERY XLarge incision Weeks ‘at home and months of pain X Injuries High X Pain cost of care X Complications COMPLICATION RATES ae FROM INCISION 15-20% MINIMALLY- > EXISTING — OPEN INVASIVE SINGLE-PORT SURGERY SURGERY ROBOTS DOMINANCE awe ee > Even more injury 39
Slide 11: Limitations of Robotic Surgery Today
Vv LIMITATIONS OF ROBOTIC SURGERY TODAY $ HIGH COST Capital and service costs >$2M investment High upfront cost and burdensome service contracts are often prohibitively expensive, especially for outpatient settings DIFFICULT TO USE ‘Steep learning curves and device-specifie training requirements Sur
Slide 12: v / ji —_ - | i -
v / ji —_ - | i -
Slide 13: Our Solution
Slide 14: The System
Vv THE SYSTEM 9 1.6cm 360 meen 3D SCREEN PROPRIETARY SOFTWARE DEGREES OF SINGLE vesrees SURGEON FREEDOM PER ARM INCISION! view Lower \ F years PATIENT CART 30+ 34'wide 28 PATENTS ISSUED FITS THROUGH ANY SENSORS PER ARM AND PENDING? STANDARD DOOR INSIDE PATIENT CAMERA AND INSTRUMENT ARMS
Slide 15: Less Invasive While Maximizing Capabilities
Vv LESS INVASIVE WHILE MAXIMIZING CAPABILITIES ONE 1.5CM'TROCAR = HUMAN EQUIVALENT ANYWHERE? EVERYWHERE* PORTABLE Fits through a standard door: faster 2robotic arms and 1camera through _—_& degreesof freedom per arm ‘set upfbreak down time Tincision Fullraplicaton of surgeons upper Inandout; less co
Slide 16: Size
Vv SIZE Simple, portable, and capable—the Vicari Surgical robot fits through a standard dobr and can fit into surgical facilities withou construction buildout VICARIOUS SURGICAL ROBOTS: LEGACY SURGICAL ROBOTS
Slide 17: 360° Reach and View
Vv 360° REACH AND VIEW The Vicarious Surgical robot can work anywhere in the abdomen through a 1.5cm! incision The 9 decoupled actuators in each arm provide unprecedented dexterity inside of an ultra thin support tube LEGACY SINGLE VICARIOUS PORT ROBOTS SURGICAL Limited area where the ‘Surgeonhas fu
Slide 18: Sensing and Visualization
Vv SENSING AND VISUALIZATION A CY) tes x Cy Ws SD DEPTH MAPPING FULL MOTION FORCE SENSING TRACKING + FEEDBACK AT EVERY JOINT SKHIGH FRAME WIDE FOV AUTOFOCUS RATE TONE ADJUSTING HEAD MOUNTED LIGHTING DISPLAY
Slide 19: Economics
Vv ECONOMICS Advanced engineering enables sterile portion to be disposable with competitive cost structure 530 printed and injection molded parts with polymer fiber cables Decoupled actuators enable polymer cables and parts, lowering part costs vs traditional manufacturing over 510% = Enables steril
Slide 20: Market Research
Vv MARKET RESEARCH FEATURES Surgeons and administrators reacted positively to the features that our surgical robot provides. Their favorite features are unique to our technology Like it because it can articulate in 3802 and provides a camera that allows for instruments to alwaysbe in view This is wh
Slide 21: Market Research: Competitor Comparison
Vv MARKET RESEAR COMPETITOR COMPARISON ~~ a) Independent blinded study with surgeons and hospitals shows over 4 out of § score(very easy sell), well above competing solutions CH COMPARED TO MANUAL MINIMALLY INVASIVE SURGERY 42 — COMPARED TO LEGACY SURGICAL ROBOTS 5 [Major Breakthrough 4lImportant Ad
Slide 22: FDA Designated Breakthrough Technology
Vv FDA DESIGNATED BREAKTHROUGH TECHNOLOGY Our product is the only surgical robot to receive a breakthrough designation from the FDA indicating that they agree with our product potential for clinical benefit! Preece =) rover = | 7 Hospital reimbursement may be higher CMS has a well-established pathwa
Slide 23: Our Pathway to Commercialization
_ OUR PATHWAY TQ ~~ ~COMMERCIALIZATION M
Slide 24: Expected Roadmap
Vv EXPECTED ROADMAP
Slide 25: Ventral Hernia Regulatory Strategy
Vv VENTRAL HERNIA REGULATORY iitancot cr product offering focused STRATEGY geese al Hernia repair Our regulatory strategy enables expedited ‘iia » a filing while reducing risk by adopting a phased and scalable approach 510(k) clearance is focused on proving ‘substantial equivalence of technology com
Slide 26: Our Market, Our Potential
= OUR MARKET, OQUR-POTENTIAL
Slide 27: First Indication: Ventral Hernia
Vv FIRST INDICATION: VENTRAL HERNIA MARKET SIZE" EXISTING MEDICARE REIMBURSEMENTS (MS provides an unfettered path to coverage, beginning as soon as the same day as FDA market autharization for breakthrough devices” MEDICARE REIMBURSEMENT FOR EACH PROCEDURE? ‘Simple Repair $5615 20% Incisional Hernia
Slide 28: Initial Addressable Market
Vv INITIAL ADDRESSABLE MARKET TOTAL INITIAL ADDRESSABLE MARKET ST36B" -7.0M ALL OTHER HERNIA? (-1.5M us) 11.5 GALLBLADDER PROCEDURES* (-2.3M us) 39M ABDOMINAL PROCEDURES ADDRESSABLE BY vicaRIOUS’ 13.4" GI PROCEDURES* (-2.8mus) TAN 2023 2024 2025 2026 2027
Slide 29: Financial Projections
Vv FINANCIAL PROJECTIONS Significant revenue potential with modest adoption: $tbn in revenue by 2027 with under 1% adoption Growing relevance of consumables as installed base expands REVENUES & GROSS MARGIN INSTALLED BASE -SHERESGEETE a =z | MARKET PENETRATION
Slide 30: Select Public References
Vv SELECT PUBLIC REFERENCES Oinarr “inspire ss pulmgiX| nanox Outset - 10.2x 10.4x 23.1% GRR ©cuardant Orteravoc - 16.3x W3.5x 22.0% INTUITIVE $92.0B 12.1x 1.x 1.9% V7 wicarious S1 1B
Slide 31: Transaction Overview
Vv TRANSACTION OVERVIEW Vicarious is preparing to go public through a business combination with 08 and is raising $115 million’ through a PIPE to further support long-term development plans in ein aa on de 203 aap aa aan near yea alee snsasiaoxeurar) wt baseman ‘ining SOURCES eau aor asty USES pity
Slide 32: Additional Information About the Proposed Business Combination and Where to Find It
Additional Information About the Proposed Business Combination and Where to Find It The proposed business combination will be submitted to shareholders of D8 Holdings Corp. (“D8 Holdings”) for their consideration. D8 Holdings has filed a registration statement on Form S-4 (the “Registration Statemen